기압외상 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the barotrauma market size is expected to increase from USD 4.12 billion in 2025 to USD 4.35 billion in 2026 and reach USD 5.76 billion by 2031, growing at a CAGR of 5.76% over 2026-2031.

This report is Segmented by Type (Ear, Sinus, Pulmonary, Others), by Offering (Diagnosis [Physical Exam, Otoscopy, Audiometry, X-Ray, CT Scan, and More], Treatment [Conservative, Medications, Oxygen Therapy, Recompression, Surgery]), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are in Value (USD).

Global Barotrauma Market Trends and Insights

Rising Recreational Diving and Aviation Exposure Driving Barotrauma Incidence

The barotrauma market is exposed to a steadily larger traveler base as global air traffic reached 4.97 billion passengers in 2025, while demand rose 5.3% and the global load factor reached 83.5%. The United States alone recorded 890.1 million passengers in 2025, which shows how large the recurring exposure base has become for aviation-related ear and sinus presentations in routine care settings. Recreational diving adds another meaningful layer because the CDC estimated 0.6 million to 3.5 million active scuba divers in the United States, and this population experiences repeated pressure transitions rather than one-time exposure.

This exposure pattern matters because ear and sinus cases often begin as mild events, but they still create recurring medication demand, ENT consultations, and follow-up visits within the formal care pathway. Even though IATA expects traffic growth to moderate in 2026, the installed base of frequent flyers remains large enough to support steady case generation for the barotrauma market across primary care, urgent care, and specialist ENT channels.

Expanding ICU Ventilation and Pressure Injury Detection Broadening the Clinical Landscape

The barotrauma market is also expanding through critical care because pulmonary injury in mechanically ventilated patients now contributes a larger and more visible share of case identification. A 2025 clinical review stated that pulmonary barotrauma in ventilated adults now averages 10% or less under modern low-tidal-volume practice, yet the absolute number of ventilated patients remains high across aging and higher-capacity hospital systems.

A 2025 Bayesian meta-analysis across 4,298 ICU patients found that respiratory rate and driving pressure were more important correlates than peak inspiratory pressure alone, which is pushing clinicians toward broader monitoring logic. That shift supports stronger demand for respiratory monitoring, CT-based escalation, and multidisciplinary ICU workflows within the barotrauma market because complex pulmonary cases rarely fit a single-parameter protocol.

High Cost of Hyperbaric and Specialist Care Limiting Access in Constrained Markets

Cost remains a clear brake on the barotrauma market, especially where hyperbaric treatment sits outside routine coverage or depends on long travel to a single center. Hyperbaric oxygen therapy typically costs USD 200 to USD 400 per session, and severe decompression illness may require 20 to 40 sessions, which pushes total episode costs to USD 4,000 to USD 16,000 based on the treatment. Many private insurers still treat HBOT as experimental or investigational for selected indications, which leaves patients with significant out-of-pocket exposure and makes referral decisions less predictable. Capacity expansion is expensive at the provider level as well, and Baraga County Memorial Hospital awarded a USD 300,000 construction contract in 2025 for its first HBOT facility in Michigan. The capital burden rises much further for multiplace systems, while recompression remains the accepted standard for severe decompression illness, so financially constrained regions face both supply and affordability barriers at the same time.

Other drivers and restraints analyzed in the detailed report include:

1. Wider Access to Hyperbaric and ENT Care Extending the Patient Catchment
2. AI-Assisted Early Diagnosis and Triage Reshaping Diagnostic Workflows
3. Underdiagnosis of Mild Cases in Primary Care Compressing the Addressable Market

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Ear barotrauma held 52.36% of 2025 revenue, the largest share within the barotrauma market share, because it remains the most common pressure-related injury across diving, aviation, and therapeutic exposure pathways. The segment benefits from a familiar care path that starts with decongestants and nasal corticosteroids and moves to office-based or surgical procedures only when symptoms persist or structural damage is suspected. Repeated exposure from air travel and recreational diving keeps case volumes high, which supports steady outpatient ENT demand and reliable refill activity within the barotrauma market.

Pulmonary barotrauma is projected to grow at 6.87% CAGR, giving it the fastest pace in the barotrauma market size by type through 2031. Its rise is tied to a larger mechanically ventilated ICU population and to more detailed monitoring of respiratory rate and driving pressure rather than reliance on a single pressure threshold.

Complete Report Scope:

• By Type
  • Ear Barotrauma
  • Sinus Barotrauma
  • Pulmonary Barotrauma
  • Others
• By Offerings
  • Diagnosis
    • Physical Examination
    • Otoscopy
    • Audiometry
    • X-Ray
    • CT Scan
    • Others
  • Treatment
    • Conservative Management
    • Medications
    • Oxygen Therapy
    • Recompression Therapy
    • Surgery
• By End User
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Trauma & Emergency Centers
  • Hyperbaric Treatment Centers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 41.34% of 2025 revenue and accounted for the largest share of the barotrauma market size by geography. The United States recorded 890.1 million passengers in 2025, which gives the region the largest continuous exposure base for aviation-related ear and sinus presentations in the global barotrauma market. The CDC also estimated 0.6 million to 3.5 million active scuba divers in the United States, which adds a large recreational diving layer to regional demand and supports recurrent outpatient ENT volumes.

Europe remained the second-largest regional cluster in the barotrauma market, supported by Germany, France, and the United Kingdom through established specialist networks and deeper hyperbaric infrastructure. Capacity expansion accelerated in 2025 and 2026 as HAUX installed Europe's largest single-site pressure chamber system in Nice, reinforcing the region's installed base and its role in chamber-centered care.

Asia-Pacific is forecast to grow at 7.23% CAGR, making it the fastest regional section of the barotrauma market. China recorded 776.1 million passengers in 2025, and Southeast Asian coastal markets add rising diving exposure on top of hospital infrastructure investment, which broadens both outpatient and acute care demand. Japan's 2025 national survey of HBO devices showed active tracking of installed hyperbaric capacity and operational readiness, which supports the region's structured growth base and suggests sustained policy and provider interest in pressure medicine.

1. AstraZeneca
2. Atos Medical
3. CellScope, Inc.
4. Cipla
5. Entellus Medical, Inc.
6. GlaxoSmithKline
7. HEINE Optotechnik
8. Hillrom Holdings, Inc.
9. Merck
10. Novartis
11. Olympus
12. Pfizer
13. Preceptis Medical, Inc.
14. Sechrist Industries, Inc.
15. Solventum Corporation
16. Stryker
17. Teva Pharmaceutical Industries

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Recreational Diving And Aviation Exposure
  • 4.2.2 Expanding ICU Ventilation And Pressure Injury Detection
  • 4.2.3 Wider Access To Hyperbaric And ENT Care
  • 4.2.4 AI-Assisted Early Diagnosis And Triage
  • 4.2.5 Hyperbaric Facility Modernization In High-Volume Centers
  • 4.2.6 Pressure-Injury Awareness Among Divers And Pilots
• 4.3 Market Restraints
  • 4.3.1 High Cost Of Hyperbaric And Specialist Care
  • 4.3.2 Underdiagnosis Of Mild Cases In Primary Care
  • 4.3.3 Specialist And Chamber Capacity Shortages
  • 4.3.4 Limited Reimbursement For Advanced Therapies
• 4.4 Value-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Industry Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Type
  • 5.1.1 Ear Barotrauma
  • 5.1.2 Sinus Barotrauma
  • 5.1.3 Pulmonary Barotrauma
  • 5.1.4 Others
• 5.2 By Offerings
  • 5.2.1 Diagnosis
    • 5.2.1.1 Physical Examination
    • 5.2.1.2 Otoscopy
    • 5.2.1.3 Audiometry
    • 5.2.1.4 X-Ray
    • 5.2.1.5 CT Scan
    • 5.2.1.6 Others
  • 5.2.2 Treatment
    • 5.2.2.1 Conservative Management
    • 5.2.2.2 Medications
    • 5.2.2.3 Oxygen Therapy
    • 5.2.2.4 Recompression Therapy
    • 5.2.2.5 Surgery
• 5.3 By End User
  • 5.3.1 Hospitals
  • 5.3.2 Specialty Clinics
  • 5.3.3 Ambulatory Surgical Centers
  • 5.3.4 Trauma & Emergency Centers
  • 5.3.5 Hyperbaric Treatment Centers
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 India
    • 5.4.3.3 Japan
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
  • 6.3.1 AstraZeneca plc
  • 6.3.2 Atos Medical
  • 6.3.3 CellScope, Inc.
  • 6.3.4 Cipla Ltd.
  • 6.3.5 Entellus Medical, Inc.
  • 6.3.6 GSK plc
  • 6.3.7 HEINE Optotechnik GmbH & Co. KG
  • 6.3.8 Hillrom Holdings, Inc.
  • 6.3.9 Merck & Co., Inc.
  • 6.3.10 Novartis AG
  • 6.3.11 Olympus Corporation
  • 6.3.12 Pfizer Inc.
  • 6.3.13 Preceptis Medical, Inc.
  • 6.3.14 Sechrist Industries, Inc.
  • 6.3.15 Solventum Corporation
  • 6.3.16 Stryker Corporation
  • 6.3.17 Teva Pharmaceutical Industries Ltd.

7 Market Opportunities & Future Outlook

• 7.1 White-space & unmet-need assessment